title: Long-term efficacy and safety of etravirine-containing regimens in a real-life cohort of treatment-experienced HIV-1-infected patients.
abstract: OBJECTIVE
  Etravirine (ETR) was approved in France in September 2008 and is used in combination with a boosted protease inhibitor (bPI) and other anti-retrovirals (ART) in HIV-infected pre-treated patients. This study aimed to report in a real-life setting the efficacy and tolerability of ETR-based regimens and factors associated with virological response.
  
  
  METHODS
  The study population included all treatment-experienced patients who initiated an ETR-based regimen between September 2008 and July 2013 from the French Dat'AIDS cohort. Analyses were performed in ART-experienced patients starting ETR after virological failure (VF) or as a maintenance therapy (MT), with or without bPI.
  
  
  RESULTS
  A total of 2006 patients (VF, n = 1014 (51%); MT, n = 992 (49%)) were included. At M12, the proportion of patients with HIV RNA < 50 copies/ml was 71.7% (72.0% and 71.1% with or without bPI) in the VF group and 90.5% (85.0% and 92.3% with or without bPI) in the MT group, without significant differences regarding the use of bPI. ETR was discontinued in 8.8% of patients for adverse events in 23.9% of cases (21.5% in VF, 29.5% in MT), treatment failure in 15.2% (16.2% in VF, 7.4% in MT) or simplification in 5.4% (4.6% in VF, 7.4% in MT). In the VF group, factors associated with virological response were a longer duration of HIV infection (OR = 2.7; p < 0.001) and baseline HIV RNA < 5 log10 copies/mL (OR = 2.1; p = 0.002).
  
  
  CONCLUSIONS
  This study shows that in ART-experienced patients ETR is well tolerated with a high efficacy when combined with other active drugs, even when the regimen does not include a bPI.
authors.affiliation: a Infectious Diseases, CHU Hôtel Dieu University Hospital , Nantes , France ;
authors.forename: Clotilde
authors.initials: C
authors.lastname: Allavena
authors.affiliation: b Infectious Diseases, AP-HP Pitié Salpétrière Hospital , Paris , France ;
authors.forename: Christine
authors.initials: C
authors.lastname: Katlama
authors.affiliation: c Infectious Diseases, Hôpital Croix-Rousse, Hospices Civils de Lyon , Lyon , France ;
authors.forename: Laurent
authors.initials: L
authors.lastname: Cotte
authors.affiliation: d Infectious Diseases, CHU de l'Archet , Nice , France ;
authors.forename: Pierre Marie
authors.initials: PM
authors.lastname: Roger
authors.affiliation: e Infectious Diseases, CHU Toulouse , Toulouse , France ;
authors.forename: Pierre
authors.initials: P
authors.lastname: Delobel
authors.affiliation: f Infectious Diseases, CHU DRON , Tourcoing , France ;
authors.forename: Antoine
authors.initials: A
authors.lastname: Cheret
authors.affiliation: g Infectious Diseases, AP-HP, Necker-Enfants Malades Hospital, Necker-Pasteur Infectious Diseases Center, Descartes University, Sorbonne Paris Cité , EA7327 , IHU Imagine , Paris , France ;
authors.forename: Claudine
authors.initials: C
authors.lastname: Duvivier
authors.affiliation: h Infectious Diseases, Aix-Marseille University , APHM Sainte-Marguerite, Department of Immuno-hematology , Inserm U912 (SESSTIM) , Marseille , France ;
authors.forename: Isabelle
authors.initials: I
authors.lastname: Poizot-Martin
authors.affiliation: i Infectious Diseases, CHU Besançon , Besancon , France ;
authors.forename: Bruno
authors.initials: B
authors.lastname: Hoen
authors.affiliation: j Infectious Diseases, CHU de Martinique , Inserm CIC1424 , France ;
authors.forename: André
authors.initials: A
authors.lastname: Cabie
authors.affiliation: k Janssen, Issy les Moulineaux , France.
authors.forename: Arnaud
authors.initials: A
authors.lastname: Cheret
authors.affiliation: k Janssen, Issy les Moulineaux , France.
authors.forename: Rima
authors.initials: R
authors.lastname: Lahoulou
authors.affiliation: a Infectious Diseases, CHU Hôtel Dieu University Hospital , Nantes , France ;
authors.forename: François
authors.initials: F
authors.lastname: Raffi
authors.affiliation: d Infectious Diseases, CHU de l'Archet , Nice , France ;
authors.forename: Pascal
authors.initials: P
authors.lastname: Pugliese
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009570:Nitriles; D011446:Prospective Studies; D011724:Pyridazines / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use*; D011743:Pyrimidines; D016896:Treatment Outcome
chemical_list: D019380:Anti-HIV Agents; D009570:Nitriles; D011724:Pyridazines; D011743:Pyrimidines; C451734:etravirine
keywords: HIV; NNRTI; etravirine; tolerability; virological efficacy